臨床研究等提出・公開システム

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure (LUMINARA)

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure (LUMINARA)

Hibi Kazushige

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi

RD-clinical-information-Japan@astrazeneca.com

Hibi Kazushige

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi

+81-6-4802-3533

RD-clinical-information-Japan@astrazeneca.com

Recruiting

July. 05, 2024

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

- Participants must have a pre-existing diagnosis of HF NYHA FC II to IV.

- Participants must be on stable HF standard of care medication for at least 4 weeks prior to Screening.

- Minimum body mass index (BMI) of 18 kilograms per meter square (kg/m^2) at Screening.

- For female participants, the participant must not be pregnant or lactating and must be of non-childbearing potential.

- All male participants should refrain from fathering a child or donating sperm until 3 months after the final study Follow-up Visit. Non-sterilised male participants should avoid fathering a child either by true abstinence or use of a condom for all sexual intercourse with a female partner of childbearing potential from the first dose until 3 months after the final Follow-up Visit.

- Historical or current evidence of a clinically significant disease or disorder including, but not limited to:

1. Myocardial infarction, stroke, transient ischaemic attack, coronary artery bypass grafting, or percutaneous coronary intervention within 12 weeks prior to Screening or transcatheter structural heart interventions or cardiac valve surgery within 6 months prior to Screening.

2. Sarcoidosis, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic (obstructive) cardiomyopathy.

3. History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency.

4. Amyloidosis, Fabry disease, or haemochromatosis.

5. Pericardial disease (i.e., visually significant white pericardium on echocardiogram).

6. Known coagulation disorders.

7. Current diagnosis of active hepatitis.

8. Severe pulmonary disease that is not expected to improve over time, as assessed by the investigator.

9. Decompensated HF or any cardiopulmonary hospitalisation within 4 weeks prior to Screening.

10. History of active malignancy within 2 years, except for fully excised or treated basal cell carcinoma, or 2 or less squamous cell carcinomas of the skin and participants who are under investigation for breast or cervical cancer, including participants with a pap smear of grade 3 or more.

- History of hypersensitivity to drugs with a similar chemical structure or class to AZD5462 or any component of AZD5462 drug product.

- Known history of drug or alcohol abuse within 24 months of Screening.

- Congenital long QT syndrome or history of QT prolongation associated with other medications that required discontinuation of that medication.

- Cardiac ventricular arrhythmia that requires treatment.

- History of or anticipated heart transplant.

- Current or planned bi-ventricular assist device implantation.

- Any planned highly invasive cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter etc).

- Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody at Screening.

- Known to have historically tested positive for Human immunodeficiency virus.

Both

Chronic Heart Failure

Drug: AZD5462, Placebo

Cohort A and B: Change from Baseline in Ejection Fraction [ Time Frame: From Baseline to Week 25 ]
To evaluate the effect of AZD5462 after treatment in participants with HF.

+81-748-33-3151

May. 16, 2024

Yes

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Bulgaria/Czech Republic/Hungary/Denmark/India/Poland/Slovakia/Netherlands/United States